Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -62.76% is in line with its 5-year average of -62.65%, near the high end of its 5-year range (-1057.14%–115.20%).
200.61% below its 12-month average of 62.38%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -16.90%.
GROSS MARGIN
-62.76%
GROSS MARGIN AVG TTM
62.38%
GROSS MARGIN AVG 3Y
-20.23%
GROSS MARGIN AVG 5Y
-62.65%
GROSS MARGIN AVG 10Y
-13.03%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-200.61%
CURRENT VS 3Y AVG
-210.27%
CURRENT VS 5Y AVG
-0.18%
CURRENT VS 10Y AVG
-381.80%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
43.54%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
-244.14%
vs the sector median at left
Market Cap
$122.96M
Gross Margin
58.78%
TTM Avg
29.39%
3Y Avg
14.70%
5Y Avg
9.80%
Market Cap
$121.22M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$119.72M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$129.68M
Gross Margin
33.47%
TTM Avg
39.70%
3Y Avg
43.04%
5Y Avg
44.80%
Market Cap
$117.21M
Gross Margin
11.17%
TTM Avg
22.02%
3Y Avg
17.41%
5Y Avg
13.61%
Market Cap
$117.11M
Gross Margin
90.14%
TTM Avg
48.16%
3Y Avg
49.08%
5Y Avg
32.72%
Market Cap
$116.54M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cibus, Inc. (CBUS) | $123.66M | -62.76% | 62.38% | -20.23% | -62.65% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | 58.78% | 29.39% | 14.70% | 9.80% |
| Entera Bio Ltd. (ENTX)vs › | $125.44M | 0.00% | 2.48% | -4.54% | 5.72% |
| enGene Holdings Inc. (ENGN)vs › | $121.22M | 0.00% | 0.00% | 0.00% | 0.00% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Health Catalyst, Inc. (HCAT)vs › | $129.68M | 33.47% | 39.70% | 43.04% | 44.80% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.21M | 11.17% | 22.02% | 17.41% | 13.61% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.11M | 90.14% | 48.16% | 49.08% | 32.72% |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | 67.34% | 64.03% | 72.89% | 33.80% |
| Freenome, Inc. (FRNM)vs › | $132.31M | N/A | N/A | N/A | N/A |
Gross Margin
-62.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -16.90% |
| 2026-03-31 | 28.79% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | -35.97% |
| 2024-09-30 | 115.20% |
| 2024-06-30 | -106.80% |
| 2024-03-31 | -224.22% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | -254.53% |
| 2023-06-30 | -268.53% |
| 2023-03-31 | -1057.14% |
| 2022-12-31 | -795.24% |
| 2022-09-30 | -840.48% |
| 2022-06-30 | -858.54% |
| 2022-03-31 | -1056.25% |
| 2021-12-31 | -3.14% |
| 2021-09-30 | -6.69% |
| 2021-06-30 | 2.97% |
| 2021-03-31 | -53.23% |
| 2020-12-31 | -35.44% |
| 2020-09-30 | -34.71% |
| 2020-06-30 | -130.65% |
| 2020-03-31 | -63.40% |
| 2019-12-31 | -42.33% |
| 2019-09-30 | -18.91% |
| 2019-06-30 | -59.31% |
| 2019-03-31 | -139.49% |
| 2018-12-31 | -17600.00% |
| 2018-09-30 | -1218.52% |
| 2018-06-30 | -9.69% |
| 2018-03-31 | -1318.18% |
| 2017-12-31 | 26.34% |
| 2017-09-30 | -1152.27% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 100.00% |
| 2016-06-30 | 13.79% |
| 2016-03-31 | 5.66% |
